Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma.
ESMO open（2023）
摘要
ClinicalTrials.govNCT02684006; https://clinicaltrials.gov/ct2/show/NCT02684006.
更多查看译文
关键词
avelumab,immunotherapy,phase III,renal cell carcinoma,risk factor
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要